Literature DB >> 16210657

The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model.

Akemi Ozaki1, Yoh-ichi Seki, Atsuki Fukushima, Masato Kubo.   

Abstract

Allergic conjunctivitis (AC) is a common allergic eye disease characterized by clinical symptoms such as itchiness, conjunctival congestion, elevated Ag-specific IgE, mast cell activation, and local eosinophil infiltration. In this study we established a murine model for Ag-induced AC to understand the pathogenesis of the disease. Cell transfer experiments indicated that AC can be divided into early and late phase responses (EPR and LPR). EPR was associated with IgE responses, leading to itchiness, whereas LPR was characterized by local eosinophil infiltration. Both EPR and LPR were significantly inhibited in STAT6-deficient mice, and adoptive transfer of Th2 cells reconstituted LPR. Furthermore, SOCS3 was highly expressed at the disease site, and T cell-specific expression of SOCS3 deteriorated clinical and pathological features of AC, indicating that Th2-mediated SOCS3 expression controls the development and persistence of AC. Reduction of the expression level in SOCS3 heterozygous mice or inhibition of function in dominant-negative SOCS3 transgenic mice clearly reduced the severity of AC. In contrast, constitutive expression of SOCS5, a specific inhibitor of IL-4 signaling, resulted in reduced eosinophil infiltration. These results suggest that negative regulation of the Th2-mediated response by dominant-negative SOCS3 and SOCS5 could be a target for therapeutic intervention in allergic disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210657     DOI: 10.4049/jimmunol.175.8.5489

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Regulation of CD4+ T-cell polarization by suppressor of cytokine signalling proteins.

Authors:  Camille A Knosp; James A Johnston
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

2.  Interleukin 10 and transforming growth factor beta contribute to the development of experimentally induced allergic conjunctivitis in mice during the effector phase.

Authors:  A Fukushima; T Sumi; K Fukuda; N Kumagai; T Nishida; H Yagita; H Ueno
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

Review 3.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

4.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 5.  Type 2 cytokines: mechanisms and therapeutic strategies.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2015-04-17       Impact factor: 53.106

Review 6.  Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase.

Authors:  Ciriana Orabona; Maria Teresa Pallotta; Ursula Grohmann
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

7.  B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis.

Authors:  Waka Ishida; Ken Fukuda; Mina Kajisako; Tamaki Sumi; Hironori Matsuda; Hideo Yagita; Atsuki Fukushima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-22       Impact factor: 3.117

8.  Conjunctival macrophages act as antigen-presenting cells in the conjunctiva during the development of experimental allergic conjunctivitis.

Authors:  Waka Ishida; Ken Fukuda; Mina Kajisako; Ayako Takahashi; Tamaki Sumi; Nico van Rooijen; Atsuki Fukushima
Journal:  Mol Vis       Date:  2010-07-10       Impact factor: 2.367

Review 9.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

Review 10.  Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

Authors:  Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2009-10-30       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.